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Hemostatic Adjuncts in 
Orthopedic Surgery: Innovations 
in Technique, Technology, and 
Biosurgical Applications
Andrew Konopitski and Chinenye Nwachuku
Abstract
Significant blood loss is an obstacle frequently encountered in orthopedic 
surgery in both elective and trauma settings. Notwithstanding the nature of ortho-
pedic surgery creates a unique environment, where hemostasis may be difficult to 
achieve. In total hip and knee arthroplasty, freshly cut bone edges bleed persistently 
and often do not respond to typical hemostatic methods utilized in soft tissues. 
Spine surgery requires strict adherence to hemostatic principles as uncontrolled 
bleeding can result in compression of neural elements. Blood loss in orthopedic 
trauma presents a highly variable environment where methods of hemostasis must 
match the severity of the injury. Lastly, orthopedic tumor procedures often require 
bloodless fields in order to limit the risk of hemostatic spread. The following 
chapter takes a subspecialized approach to blood loss management in orthopedic 
surgery, including perioperative management of anticoagulant medications, proto-
cols for utilization of pharmacologic agents, and techniques for the application of 
topical hemostatic compounds.
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1. Introduction
Orthopedic procedures are among the most common elective and non-elective 
surgeries performed in the United States every year. Though common, these pro-
cedures are associated with excessive bleeding and a high demand for transfusions 
[1–3]. Common surgeries where significant blood loss can be expected include total 
hip and knee replacements, instrumented spinal fusion or deformity correction, 
wide resection for bone or soft tissue tumors and trauma to long bones, especially 
those of the lower extremities and pelvis. Maintaining hemostasis in these environ-
ments is of utmost importance, but many orthopedic subspecialties have surgical 
cases which present unique challenges in blood management. During decompres-
sion of the spinal canal, surgeons must be vigilant of the effects that hemostatic 
agents may have on neural structures. Joint arthroplasty procedures are often 
associated with bleeding from the bony edges which is not amenable to techniques 
commonly used for hemostasis in soft tissues, and orthopedic traumatologists must 
frequently manage mangled limbs with multifaceted approaches.
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To put the importance of blood management in perspective, one must look at the 
prevalence of transfusions among orthopedic populations. Though the rate of hip 
and knee arthroplasty has steadily increased over the last decade, transfusion rates 
have remained stable, but the type of transfusion has shifted from pre-donated 
autologous blood to allogenic blood transfusions [1]. Between total hip arthroplasty 
(THA) and total knee arthroplasty (TKA), it has been demonstrated that THA is 
associated with higher rates of perioperative transfusions, especially if the patient 
is anemic pre-operatively. In their study of national trends in transfusion require-
ments in lower extremity arthroplasty, Yoshihara et al. cited transfusion rates of 
18% and 11% for THA and TKA, respectively [1].
Similarly, spine surgery has seen a significant increase in allogenic transfusions, 
while pre-donated autologous blood transfusion has declined [2]. When translated 
to the pediatric population, major deformity corrections of the spine have consis-
tently found that 30% of patients will require a transfusion and these rates may 
increase with the presence of neuromuscular syndromes or non-neuromuscular 
comorbidities [3]. The PREPARE study performed in 2015 was a large observational 
study assessing the value of patient blood management (PBM) programs in the 
context of major joint or spine surgery. This study found that PBM centers not only 
optimized patients better pre-operatively, but also found that patients who entered 
surgery anemic had higher complication rates [4].
In the realm of tumor surgery, orthopaedists are often called upon to stabilize 
compromised long bones in the setting of metastatic disease to avoid pathologic 
fracture. In this setting, patients are often deconditioned and can be expected to 
receive an average of 2.5 units of packed red blood cell (PRBC) transfusions in the 
post-operative period [5].
Lastly, orthopedic trauma to the lower extremities and pelvis are associated with 
an extremely high rate of transfusion. Over one-third of the patients who sustain a 
fracture of the femur will require a transfusion within 48 h with an average transfu-
sion volume of 2 units PRBC [6].
While transfusions themselves place the patient at risk for transfusion reactions, 
disease transmission, and increased overall cost of care, there is a preponderance of 
data which shows that receiving a transfusion in the perioperative period places the 
patient at risk for post-operative complications. Across all subspecialties, transfu-
sions have been shown to increase length of stay, cardiac events, sepsis, wound 
infections, and even mortality [7–10].
It is imperative to develop a comprehensive approach to blood management, as 
many orthopedic surgical procedures place patients at risk for blood transfusions, 
leaving both patients and the healthcare system at risk of negative outcomes. The 
goal of this chapter is to outline several options by which surgeons can optimize 
patients in the perioperative setting. This includes pre-operative management of 
anticoagulant and antiplatelet agents, intra-operative techniques, new technology, 
and use of biosurgical innovations throughout the perioperative period to minimize 
blood loss.
1.1 Perioperative management of anticoagulant and antiplatelet medications
Given the expected blood loss associated with certain orthopedic surgeries, 
patients taking prophylactic or therapeutic anticoagulants may require the effects 
of these medications to be reversed in a controlled fashion. Unfortunately, this 
reversal can place patients at risk for arterial thromboembolism (ATE) or venous 
thromboembolism (VTE) due to a rebound hypercoagulability resulting from 
increased thrombin generation. The risk of ATE is relatively low in patients 
with mechanical valves or atrial fibrillation (0.6%), but up to 70% of those 
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who develop an ATE can suffer a cerebral embolism which can leave patients 
with varying degrees of disability [11]. Conversely, patients who do not have 
the effects of these medications adequately reversed are left at an increased risk 
of post-operative hemorrhage leading to higher rates of infection and possible 
compartment syndrome [11].
Warfarin is one of the oldest anticoagulation agents on the market and works 
by inhibiting the reduction of vitamin K into vitamin K epoxide, which is required 
for gamma carboxylation of many clotting factors including II, V, VII, and X. The 
advantage of warfarin is that it can be easily measured via international normalized 
ratio (INR) and has many reversal agents. Troublesome aspects of warfarin include 
difficulty maintaining proper therapeutic levels which requires frequent testing 
as well as cross reactivity with many other medications, foods, and supplements. 
Studies have shown that an INR > 1.8 is an independent risk factor for post-operative 
hemorrhage, and an INR of >1.4 is a contra-indication to spinal anesthesia as it 
places the patient at risk for epidural hematoma [12, 13].
The mode of reversal for warfarin can be dictated by the timeframe of surgery. 
Urgent surgeries (within 24 h) require more aggressive measures than semi-urgent 
surgeries (24–72 h) and elective surgeries. For cases that require urgent intervention, 
prothrombin concentrate complex (PCC) and fresh frozen plasma (FFP) are agents 
that may be utilized. PCC is a balanced mixture of coagulation factors II, V, VII, and 
X. PCC has the advantage of being administered in small volumes over the course of 
several minutes and can reverse INR within 3–4 h. Disadvantages of PCC include a 
lack of intrinsic pathway coagulation factors and increased risk of patient developing 
thrombosis due to rapid reversal of anticoagulant. FFP contains all coagulation 
factors except for IX. It is administered in larger volumes over the course of hours. 
While it does provide a more gradual correction than PCC, the effects can be tran-
sient leaving the patient under-corrected at the time of surgery. Furthermore, FFP 
has a risk of disease transmission and the larger transfusion volumes can contribute 
to CHF and fluid overload. Key to FFP administration is monitoring INR just prior 
to surgery [11, 14, 15].
In the case of semi-urgent surgery, vitamin K has the safest side-effect profile. 
This method of anticoagulant reversal works by providing more vitamin K substrate 
for reduction by vitamin K epoxide and eventual gamma carboxylation of factors 
II, V, VII, and X. Though studies have shown intravenous (IV), intramuscular (IM), 
and per-oral (PO) vitamin K to be effective, each has its advantages. IV and IM vita-
min K effects are more rapid when compared to oral administration, but are associ-
ated with higher rates of anaphylaxis in IV forms and cutaneous reactions with IM 
administration. For oral dosing, 2.5–5 mg of vitamin K is given and INR is measured 
until the goal is reached. Depending on the formulation, 73–93% of patients with 
presenting INR > 4.0 can achieve an INR < 2 within 24 h of PO vitamin K adminis-
tration [16].
In elective surgery, patients can be allowed to drift down to a safe INR. Over 
90% of patients with INR levels >2.0 can fall below 1.5 after 5 days [17]. It is recom-
mended that patients undergoing major orthopedic surgery should have an INR of 
<1.3. Patients at high risk for thrombosis may be transitioned to bridging therapy 
with unfractionated heparin or low molecular weight heparin. Table 1 outlines 
recommendations for bridging therapy based on thrombosis risk. Pneumatic 
compression stockings should be employed whenever possible [11].
Perioperative management of direct oral antocoaculants (DOAC), formerly 
known as novel anticoagulants, varies by agent. While they provide an advantage 
over warfarin with dosing consistency, they lack a means of reliable point-of-care 
measurement. While no standard protocol exists for the management of DOACs 
in urgent orthopedic surgery, some studies suggest that surgery is safe to perform 
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within 24 h as long as the treating teams remain vigilant of blood loss and transfu-
sion requirements [18–20]. In the semi-urgent or elective setting, patients may be 
allowed to safely drift to subtherapeutic levels according to the medication half-life. 
Pre-operative recommendations for DOAC management as well as availability of 
reversal agents are listed in Table 2.
Lastly, in reference to anti-platelet agents, no standardized protocol has been 
developed. Aspirin has been heavily studied in the pre-operative setting, but 
evidence has been conflicting in relation to intra-operative bleeding or post-
operative complications. Newer agents, such as clopidogrel or prasugrel, have 
limited high-quality, randomized controlled trial (RCT) data in non-cardiac sur-
gery. A Cochrane review article in 2018 evaluated evidence available in the form 
of RCT for continuing antiplatelet therapy in non-cardiac surgery. They found 
no evidence of increased mortality or ischemic events (Grade: Low certainty) 
post-operatively and no evidence of increased bleeding requiring a transfusion 
(Grade: Moderate certainty) [21]. Historically, pooled platelets, desmopressin, 
and recombinant factor VII have been used to acutely counteract the effects 
of irreversible antiplatelet agents, though no prospective studies have been 
Agent Duration of pre-op 
ATI
CrCl correction Reversal agent
Dabigatran 
(Pradaxa)
2 days 4 days w/CrCl 
<50 mL/min
idarucizumab (Praxbind)
Rivaroxaban 
(Xeralto)
2 days 3 days w/CrCl 
<30 mL/min
Recombinanat factor Xa 
(Andexxa)
Apixaban (Eliquis) 2 days 3 days w/CrCl 
<30 mL/min
Recombinanat factor Xa 
(Andexxa)
Endoxaban 
(Savaysa)
2 days 3 days w/ CrCl 
<30 mL/min
None
Aspirin 7–10 days N/A Pooled platelets
Clopidogrel 
(Plavix)
7–10 days N/A Pooled platelets
Duel antiplatelet Tx Clopidogrel 7-10d 
Aspirin 5d
N/A Pooled platelets
ATI—antithrombotic interruption; CrCl—creatine clearance
Table 2. 
Pre-operative management of direct oral anticoagulants (DOAC) and antiplatelet agents.
Thrombosis 
risk
Stop WF Begin LMWH 
bridge
Restart WF Stop LMWH 
bridge
High 5 days pre-op Once INR <1.8 
until 24 h prior 
to surgery
Evening s/p 
Surgery
Once INR is 
therapeutic
Intermediate Individualized, multidisciplinary approach Evening s/p 
Surgery
Once INR is 
therapeutic
Low 5 days pre-op No need for 
bridging Tx
Evening s/p 
Surgery
N/A
WF—warfarin; INR—international normalized ratio; LMWH—low molecular weight heparin.
Table 1. 
Bridging therapy recommendations for patients on warfarin therapy.
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conducted to evaluate effectiveness in orthopedic surgery [11]. When possible, 
surgery should be avoided in patients within 6 months of cardiac stent placement 
with an ideal delay of 1 year. Table 2 contains recommendations for management 
of antiplatelet agents in elective orthopedic surgery.
2. Hemostasis in total hip and knee arthroplasty
Hip and knee arthroplasty are among the most commonly performed ortho-
pedic procedures in the United States and they carry a unique set of challenges 
related to hemostasis. When cutting bony surfaces, surgeons are left with a bleed-
ing bone edge which is recalcitrant to many soft tissue hemostatic techniques such 
as direct electrocautery. These bleeding edges, if not addressed, can contribute 
to both total measured blood loss as well as hidden blood loss. Below will outline 
biosurgical, mechanical, and technical methods for controlling blood loss during 
arthroplasty.
2.1 Tranexamic acid (TXA)
Perhaps, the most heavily studied agents for reducing blood loss is tranexamic 
acid (TXA). TXA is a synthetically derived analog of the amino acid lysine, and 
works by competitively binding the lysine binding site of plasminogen. This pre-
vents plasmin from cleaving fibrin, thereby decreasing fibrinolysis and allowing for 
stable clot formation [22, 23]. The primary advantage of TXA is the minimal side-
effect profile and plurality dosing routes including topical, intravenous, and oral.
2.1.1 Topical
Topical TXA is an unconventional mode of administration but carries several 
advantages including direct application to the source of bleeding, very little sys-
temic absorption, and the ability to deliver the agent in higher concentrations. 
While no standard protocol exists for topical TXA in joint arthroplasty, the method 
used by Konig et al. has been replicated in several RCTs. For THA, 3 g of TXA is 
diluted in saline to make 150 mL of TXA concentrate. First, a 25 × 25 cm gauze 
is soaked in 50 mL of concentrate and packed into the acetabulum after reaming 
where it is left for 3 min. A second gauze soaked with 50 mL of TXA is packed into 
the femoral canal after broaching ×3 min. The final 50 mL of TXA concentrate 
is injected into the hip joint after fascial closure [24]. The results by Konig et al. 
were supported in a double-blind RCT by Yue et al. showing that topical TXA 
significantly decreases intra-operative blood loss, drainage rates, transfusions and 
hemoglobin drop on post-operative days 1 and 3 [25]. In a meta-analysis including 
over 2500 patients, Chen et al. found similar results without a reciprocal increase in 
the rate of DVT [26].
Konig et al. also developed a protocol for topical TXA in TKA, which involves 
diluting 3 g of TXA in 100 mL of saline and injecting it into the knee after closure 
[24]. The drain remains clamped for 1 h, after which it is placed to suction. This 
protocol was supported in a prospective RCT by Hamlin et al. who showed lower 
rates of transfusion and blood loss compared to IV TXA [27]. An alternative 
method described in a prospective RCT by Abdel et al. dilutes 3 g TXA in 45 mL of 
saline. The wound is irrigated with this solution after cementation and allowed to 
sit for 5 min before being suctioned away. This study found equivalence of topical 
TXA to IV TXA [28].
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2.1.2 Intravenous
Intravenous TXA is the most common route of administration and also the most 
studied. Notwithstanding, there are a number of dosing protocols with no studies 
showing superiority of one dosing regimen over another. Low-dose TXA studies 
may use a weight-based protocol of 10–20 mg/kg pre-operatively, while higher 
dose protocols use up to 20 mg/kg administered pre-, intra-, and post-operatively. 
Other institutions use a standard 1 g of TXA IV pre-operatively before tourniquet 
deflation. As of yet, there has been no significant difference between protocols in 
relation to blood loss, transfusion rates of drain output. Some evidence does exist 
showing that TXA administered 10 min prior to incision is more effective than 
TXA given 10 min prior to tourniquet deflation in TKA [29, 30]. Fillingham et al. 
has published two large meta-analyses evaluating IV TXA in TKA and THA. In 
TKA, evidence does support use, but could not come to a conclusion regarding 
formulation, dose, or re-dosing. It did suggest that TXA should be administered 
pre-incision [31]. For THA, TXA was clearly effective in improving blood loss, 
transfusion rates, and hemoglobin drops, but no conclusion could be reached in 
regard to formulation, dosing, re-dosing, or timing [32].
2.1.3 Oral
The last route of administration for TXA is PO. The primary advantage of oral 
TXA over IV formulations is cost. Several studies have shown equivalence between 
intravenous and oral TXA in both THA and TKA [33–35]. The most commonly 
studied dose is 1.95 g, which is commercially available and is taken 2 h prior to 
incision. It is unclear whether multiple PO doses of TXA offer any advantage over 
a single dose. A full list of protocols and recommendations regarding TXA can be 
found in Table 3.
While TXA is generally deemed safe for a vast majority of patients, those with a 
history of pulmonary embolism, venous thromboembolism, stroke, cardiac stents, 
cardiac bypass, or pro-coagulation disorders have been historically contra-indicated 
for TXA. These recommendations have been precautionary in nature, but several 
studies have found that even in these “high risk” patients, TXA has not been associ-
ated with increased thromboembolic (TE) complications. In a small retrospective 
study, 240 patients with one of the seven comorbidities listed above were given IV 
TXA and found to have no increased risk for TE event compared to controls [36]. In 
a larger retrospective cohort study, Madsen et al. compared 2766 patients receiving 
TXA treatment to 393 patients who did not. Among patients with ASA scores III/IV, 
type II diabetes mellitus, or cardiovascular disease, there was no increased rate of 
TE events [37]. Further large-scale, prospective studies need to be performed to 
define risks of TXA.
2.2 Aprotinin
Aprotinin is a nonspecific serine protease inhibitor which decreases concentra-
tions of fibrinolytic proteases such as cathepsins, kallikrein, protein C, plasmin, 
and thrombin. Inhibiting these serine proteases promotes clot formation. It is 
excreted renally and has a biphasic half-life. The rapid phase half-life is 40 min 
and the slow phase half-life is 7 h. A biphasic half-life lowers the risk of unwanted 
thrombosis and DVT formation [38].
No standardized protocol exists, but a double-blind prospective RCT performed 
by Colwell et al. in THA gave patients a loading dose of 2 million kallikrein inhibiting 
units (KIU) followed by a continuous infusion of 0.5 million KIU until the conclusion 
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of surgery. They found that this significantly reduced blood transfusion rates [39]. 
In a study of bilateral TKA, Kinzel et al. employed a weight-based protocol infused 
over 30 min during the closing stages of the first knee arthroplasty. Patients weighing 
<75 kg were administered 1million KIU, 75–100 kg were given 1.5 million KIU, and 
those weighing >100 kg were given 2 million KIU. Patients had significantly lower 
transfusion rates and drain outputs compared to controls with no complications [40]. 
These results have been repeated in a small series of patients undergoing revision 
THA, TKA, or sarcoma resection [41]. Unfortunately, aprotinin was removed from 
the US market in 2007 for concerns for renal toxicity, though it does remain an active 
ingredient in some of the topical compounds listed below [42]. Further RCT may be 
needed to explore the risks of aprotinin.
2.3 Topical thrombin-based gels
Thrombin (also known as clotting factor IIa) is converted from the inactive pro-
enzyme, prothrombin, by factor Xa. Thrombin then cleaves fibrinogen into fibrin to 
cross link platelets in a sort of brick-and-mortar structure. Topical thrombin-based 
Dose Timing
Arthroplasty
THA
IV 10–20 mg/kg 10 min pre-incision
Oral 1.95 g 2 h pre-incision
Topical 3 g in 150 mL saline 50 mL w/acetabular ream
50 mL w/femoral broach
50 mL s/p fascial closure
TKA
IV 10–20 mg/kg 10 min pre-incision
Oral 1.95 g 2 h pre-incision
Topical 3 g in 45–100 mL saline After cement polymerization or after closure
Spine
IV 10–20 mg/kg bolus
10–20 mg/kg/h infusion
10 min prior to incision through closure
Oral 1.95 g 2 h pre-incision
Topical 1 g in 100 mL saline Irrigate wound for 2–5 min prior to closure
Trauma
IV 1 g bolus
1 g infusion
Bolus w/i 8 hours of injury over 10 min
Infusion over 8 h
Oral No current literature
Topical 3 g in 30 mL saline Injected after fascial closure
Oncology
IV 15 mg/kg/h bolus
15 mg/kg/h infusion
Bolus at induction
Infusion over 8 h
Oral No current literature
Topical 1 g in 10 mL saline Sprayed over wound bed before closure
Table 3. 
Tranexamic acid recommendations by subspecialty.
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Agent Mechanism Risks
Passive
Bone Wax Intercalation within bony 
trabeculae
Impeds bone fusion, anaphylaxis, 
pro-inflammatory
Gelatin Sponge/Powders Local tamponade Mass effect near neural elements, DIC 
(powders)
Oxidized Regenerated 
Cellulose
Local tamponade Mass effect near neural elements
Chitosan Ion based muco-adherent 
activation of RBCs
None reported
Zeolite Clot scaffold, H2O sieve Exothermic reaction can cause burns
Active
Fibrin sealants Coaguation lattice for clot 
formation
Hypersensitivity reaction for brands 
containing aprotinin
Topical thrombin-based 
agents
Coaguation lattice for clot 
formation
None reported
Aprotinin Antifibrinolytic serine protease 
inhibitor
Renal toxicity
Microfibrillar collagen 
agents
Collagen scaffold for fibrin Inhibits PMMAC interdigitation, 
possible hypersensitivity
DIC—diffuse intravascular coagulation; PMMAC—polymethylmethacrylate cement; RBCs—red blood cells.
Table 4. 
List of topical hemostatic agents used in orthopedic surgery and their mechanism.
agents combine a high viscosity gel, often composed of engineered collagen gran-
ules, mixed with bovine derived thrombin. These agents are more commonly used 
in arenas of soft tissue procedures, but questions have been raised about their utility 
in arthroplasty. Again, no standardized protocol exists for use of thrombin-based 
gels in orthopedics, but two high-quality prospective RCTs used similar methods in 
TKA. The protocol involves applying 10 cc of gel to the exposed bone edges after the 
components have been placed and cement has polymerized. One study also applied 
gel to the surrounding soft tissues. The thrombin gel is allowed to sit for 2 min and 
is irrigated away [43, 44]. The most recent meta-analysis to date, Wang et al. found 
that these agents can significantly decrease mean calculated total blood loss, drain 
output, and drops in hemoglobin with minimal risk of side effects. Unfortunately, 
this meta-analysis only included five studies and further work must be done to sup-
port this practice as standard [45]. To date, no studies have evaluated the effective-
ness of thrombin-based agents in THA.
2.4 Fibrin sealants
As described above, fibrin is a coagulation cascade end product necessary for 
stable clot formation. Topical fibrin sealants seek to reproduce this final step of 
the coagulation cascade by providing exogenous clotting reagents to induce clot 
formation. While there are many proprietary fibrin sealants on the market, most 
are a combination of fibrinogen, thrombin, factor XIII, and an antifibrinolytic 
such as aprotinin or TXA. Early iterations of fibrin sealants were animal derived, 
but modern preparations are obtained via donated autologous platelet-poor plasma 
or pooled human plasma [46]. These preparations are stored as separate mixtures 
in a two chamber (or syringe) system. One chamber typically contains thrombin 
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activated with calcium chloride, and the second chamber contains fibrinogen and 
an antifibrinolytic. The contents of these two chambers are sprayed in a fine mist 
allowing for the reagents to mix and commence the clotting cascade.
Two high-quality randomized controlled trials have evaluated the effects of 
fibrin sealants in total knee arthroplasty. These studies concluded that fibrin 
sealants significantly reduce perioperative blood loss, transfusion requirements, 
hemoglobin drop, and drain output [47, 48]. The protocol for the use of fibrin 
sealant in TKA is as follows: after final components have been placed and cement 
polymerized, the joint is thoroughly irrigated. About 10–20 mL of sealant (1–2 kits) 
is then sprayed into the wound bed evenly coating exposed boney edges, muscle, 
tendon and “hidden pouches.” A drain is placed as per institutional protocol and 
layered closure was performed [47, 48].
Evidence for the use of fibrin sealants in total hip arthroplasty is also strongly 
supported in the literature. Crawford et al., in a retrospective case-control study, 
found that fibrin sealants in THA can reduce perioperative blood loss and transfu-
sion rates. These results were later echoed by the work of Wang et al. in a prospec-
tive controlled trial [49, 50]. In these studies, cemented components were used and 
10 mL of sealant was sprayed over the tissues after cement polymerization [49].
Please refer to Table 4 for the complete list of topical hemostatic agents used in 
hip and knee arthroplasty.
3. Hemostasis in major spine surgery
Hemostasis in major spine surgery presents many unique challenges. As with 
arthroplasty, bone bleeding composes a significant portion of blood loss; but unlike 
arthroplasty, the surgeon must be continuously aware of the proximity of neural 
elements in the surgical field. Post-operative hematomas may also lead to neuro-
logic complications. The presence of neural elements often precludes use of certain 
technologies such as bipolar sealers, but these challenges have also spurred innova-
tion. Some of the more specific methods of hemostasis in spine surgery are outlined 
below.
3.1 TXA
As with lower extremity arthroplasty, tranexamic acid is one of the most heavily 
researched adjuncts for hemostasis in spine surgery. All three modes of administra-
tion have been studied and are outlined below:
3.1.1 Intravenous
IV TXA remains the most common route of TXA administration in spine sur-
gery. To date, the most comprehensive meta-analysis outlining the effectiveness of 
IV TXA in spine surgery includes 18 RCTs and 18 non-RCTs. This analysis included 
cervical, thoracic, and lumbar spine surgery regardless of anterior or posterior 
approach. The type of surgery (discectomy, laminectomy, fusion, deformity cor-
rection, etc.) was not specified, but the authors did stratify studies by low-dose or 
high-dose administration of TXA. Low dose was considered a bolus of ≤10 mg/kg 
followed by ≤10 mg/kg/h infusion, and high dose was defined as a bolus ranging 
from >10 to 100 mg/kg followed by a maintenance infusion of >10 mg/kg/h there-
after. All studies had control groups receiving either a placebo of saline or no TXA 
at all. Pooled data was able to demonstrate that IV TXA reduced blood loss at every 
point of the operative cycle compared to controls regardless of dose. Interestingly, 
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there was a dose-dependent response of IV TXA in decreasing intra-operative and 
perioperative allogenic blood transfusions as well as operative times. Furthermore, 
there was no increase in the rate of post-operative complications or thromboem-
bolic complications compared to control groups regardless of dose [51].
While a definitive statement on IV dosing protocol in spine surgery cannot be 
made, the data would suggest that patients may benefit from higher dose regimens 
in respects to transfusion rates and operative times. This comes with the caveat that 
more studies need to be performed to add context.
3.1.2 Oral
Overall, there is a paucity of data evaluating the efficacy of oral TXA in major 
spine surgery. Thus far, a singular prospective RCT has been conducted comparing 
PO administration of TXA to IV TXA in thoracolumbar spinal surgery. Patients 
randomized to the oral TXA group were given 1.95 g 2 h prior to surgery. The IV 
TXA arm was administered 1 g IV TXA as a bolus prior to incision and 1 g IV TXA 
before wound closure. The authors were able to establish equivalency of PO TXA 
to IV TXA according to calculated bloods loss, transfusion rates, post-operative 
hemoglobin drops, and rates of thromboembolic events [52]. While preliminary 
data regarding PO TXA in spine surgery is promising, more high qualities need to 
be performed to establish efficacy compared to placebo controls and established IV 
TXA protocols.
3.1.3 Topical
The best evidence outlining the efficacy of topical TXA in spine surgery com-
pared to placebo controls has been published in two meta-analyses by Yerneni et al. 
and Luo et al. They were able to conclude that topical TXA can decrease total blood 
loss, post-operative hemoglobin drops, and drain outputs compared to placebo 
controls. Several protocols for the use of topical TXA were outlined, but the most 
common method was 1 g of TXA diluted in 100 mL of saline. The surgical wound 
was irrigated with this solution prior to closure and was allowed to sit for 2–5 min 
before being suctioned away [53, 54].
In an effort to compare topical TXA in spine surgery to the more commonly 
used IV TXA, Xiong et al. conducted a meta-analysis including eight Chinese RCTs. 
A compilation of 333 patients received IV TXA while 327 had topical TXA. They 
demonstrated no significant differences in blood loss, hemoglobin, hematocrit, 
fibrinogen concentrations, post-operative PT or APTT, drainage volume, and blood 
transfusions. Of note, this meta-analysis was limited to non-deformity correction 
surgeries, primarily lumbar and thoracolumbar decompression and fusions.
While more high-quality data needs to be obtained to confirm the efficacy of 
topical TXA in major spine surgery, the current body of evidence suggests that 
PO TXA is effective in decreasing blood loss, transfusion requirements, and drain 
outputs when compared to placebo and preliminary evidence shows that this route 
of administration may be equivalent to the more costly IV TXA.
To see a complete list of the protocols and recommendations for TXA in major 
spine surgery, please refer to Table 3.
3.2 Recombinant factor VIIa
Not uncommonly in major spine surgery, patients can lose the equivalent of one 
entire blood volume or more. This situation can lead to difficulty in clot formation 
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secondary to consumptive and dilutional coagulopathies. A consumptive coagu-
lopathy exists as a result of coagulation factors and platelets appropriately being 
consumed at the surgical site, while a dilutional coagulopathy results from replace-
ment of blood volume with non-plasma fluids. Traditional methods of addressing 
the relative shortage of coagulation factors and platelets is replacement therapy 
with allogenic pooled platelets or fresh frozen plasma, but these methods can be 
fairly nonspecific in their mechanism [55].
Recombinant clotting factor VIIa (rFVIIa) was originally developed to address 
intra-operative bleeding in patients with disorders of coagulation such as congenital 
hemophilia, acquired hemophilia, or antibodies to clotting factors VIII or IX. The 
theory behind using rFVIIa in patients with excessive blood loss is as follows: FVIIa 
normally works by combining with tissue factor (TF) to create FVIIa-TF complex 
which activates downstream clotting factors II, IX, and X eventually resulting in 
a thrombin burst. This thrombin burst is essential for creating a stable fibrin plug 
resistant to fibrinolysis. In situations of excessive blood loss, exogenously admin-
istering rFVIIa will selectively complex with TF at the site of injury, activating the 
clotting cascade, and leading a thrombin burst with local hemostasis [55, 56].
Thus far, limited data exists for the use of rFVIIa in major spine surgery. The 
studies available suggest that rFVIIa effectively reduces intra-operative blood loss, 
intra-operative transfusion requirements and has a sustained effect on reducing PT 
and INR [56, 57]. No standard protocol exists for dosing or timing given the limited 
patient data. One study randomized patients undergoing deformity correction sur-
gery to a treatment arm receiving 23 μg/kg beginning 30 min prior to incision, while 
another study randomized patients undergoing major spine surgery to treatment 
arms of 30, 60, or 120 μg/kg given in three separate doses only after an estimated 
10% of blood volume had been lost [56, 57]. Of these studies, no increased compli-
cations were observed in the treatment groups compared to control groups suggest-
ing that this treatment is safe. Further prospective studies are needed to determine 
efficacy, dosing, and timing of rFVIIa but preliminary results are promising for use 
in spine surgery where major blood loss is expected.
3.3 Topical hemostatic agents
The category of topical hemostatic agents in spine surgery is vast and can be split 
into passive and active agents. Both classes are discussed below. See Table 4 for a 
complete list of topical hemostatic agents used in spine surgery and their mechanism.
3.3.1 Passive hemostatic agents
3.3.1.1 Bone wax
Perhaps the oldest topical hemostatic agent in orthopedic surgery is bone 
wax. In modern times, it is employed less frequently, but it remains a mainstay in 
spine surgery and during certain approaches of the pelvis where bone bleeding is 
encountered frequently. Bone wax is derived from a combination of bees wax and 
petroleum jelly and works via mechanical intercalation within bony trabeculae to 
tamponade bleeding. Currently, no RCT has been performed to tests the overall 
effects of bone wax on blood loss in spine surgery, yet it remains a staple for many 
surgeons. One caveat of bone wax is that it can be a physical impediment to bone 
healing leading to possible pseudoarthrosis of fusion segments if used in excess. 
Bone wax can also illicit an allergic reaction in patients allergic to bee venom and 
has a local pro-inflammatory effect [58].
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3.3.1.2 Gelatin sponge/powders
Gelatin sponges are hydrophilic compounds that, when exposed to moisture, 
will expand several times their size. In the context of surgery, these sponges can 
be placed into a cavity or can be rubbed vigorously onto the surface of a bleed-
ing bone while powder is simply applied topically to a site of bleeding. Once 
deployed, the gelatin expands creating a tamponade effect. The effect of these 
sponges can be augmented with the addition of thrombin to encourage clot 
formation [59]. One benefit of gelatin-derived agents is that they do not serve 
as a physical impediment to bone healing like bone waxes. Currently, there are 
no RCTs exploring gelatin sponges/powders as they relate to blood loss in spine 
surgery. One important caveat to the use of gelatin sponges, especially in the 
arena of spine surgery, is that their expansion can cause a mass effect resulting 
in compression of neural elements. While mass effect has not been demonstrated 
by powdered gelatin agents, there has been a case report of powdered gelatin 
being inadvertently introduced intravascularly causing DIC. Given the possible 
complications, it is recommended that gelatin sponges be removed, and powders 
irrigated away [58].
3.3.1.3 Oxidized regenerated cellulose
Oxidized regenerated cellulose (ORC) is produced in a sponge-like form and 
works in a similar mechanism to gelatin sponges. No RCTs exploring the effect of 
ORC agents on blood loss in spine surgery has been performed. Similar cautions 
should be applied to these compounds as gelatin sponges [58, 59].
3.3.2 Active hemostatic agents
3.3.2.1 Fibrin sealants
Section 2.4 outlines the mechanism of action for fibrin sealants. While the 
primary use of fibrin sealants in spine surgery is aimed at augmenting dural repairs, 
these compounds have also been shown to promote hemostasis. In a 2008 study 
of 3+ level anterior cervical decompression and fusion, 2 mL of fibrin sealant was 
sprayed as a fine mist over the surgical bed before closure and a drain was placed 
as per institutional protocol. This study found that fibrin sealants significantly 
reduced post-operative drain output and length of stay [60].
3.3.2.2 Thrombin-based agents
The mechanism for topical thrombin-based agents is outlined above in the 
section on arthroplasty. Thus far, only one landmark study has been performed as 
it relates to topical thrombin-based agents and hemostasis in spine surgery. The 
multicenter, randomized controlled trial compared a novel thrombin-based agent 
to gelatin sponges soaked in thrombin. Compared to the gelatin sponge group, the 
novel thrombin-based agent was able to control bleeding within 10 min in a greater 
proportion of patients, and time to hemostasis was significantly shorter [61]. While 
this data is promising, further exploration of thrombin-based topical agents should 
be performed to determine effects on intra-operative and post-operative blood loss, 
drops in hemoglobin, etc.
Please refer to Table 4 for the complete list of topical hemostatic agents used in 
major spine surgery.
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4. Hemostasis in orthopedic trauma
The surgical timeframe in orthopedic trauma varies greatly ranging from 
emergent to elective. As a result, hemostatic principles must also reflect this level 
of plasticity as the mangled extremity is managed much differently in the emergent 
setting than an ankle fracture is in the elective setting. Often, the task of achiev-
ing hemostatis has started in the pre-hospital setting and it is the responsibility of 
the surgeon and the acute trauma medical colleagues to swiftly enact some of the 
methods described below to avoid downstream complications.
4.1 Topical hemostatic agents
While previously discussed topical hemostatic agent can be utilized in the 
trauma setting, this section will focus on novel agents specifically designed for 
major extremity trauma. These agents have primarily been used in battlefield 
settings and are not currently FDA approved, but may translate to civilian first 
responders in the future.
Chitosan is a freeze-dried, deacetylated form of chitin which is applied as a ban-
dage to an exsanguinating wound. The positive surface charge of the chitin bandage 
attracts negatively charged red blood cells causing muco-adherent activation. The 
original formulation of this product was stiff and did not lend itself to being easily 
packed into wounds, but newer, more flexible iterations are now in use [62].
Zeolite is composed of biologically inert mineral granules, which act at local 
water sieves and exerts its mechanism of action in three different ways. First, by 
decreasing local concentrations of water, relative concentrations of platelets, and 
clotting factors increases. Second, the granular surface of the mineral serves as a 
medium for clot formation. Lastly, the hydration reaction of the granules is exo-
thermic creating a thermal environment ideal for clot formation. The exothermic 
properties of these agents can be exuberant and cause chemical burns. They should 
therefore be used with irrigation [62].
Please refer to Table 4 for the complete list of topical hemostatic agents used in 
orthopedic trauma surgery.
4.2 Tranexamic acid
TXA has much less robust utilization in orthopedic trauma than it does in 
arthroplasty or major spine surgery. Nonetheless, high-quality evidence exist 
showing efficacy of TXA in trauma. The 2010 Clinical Randomization of an 
Antifibrinolytic in Significant Hemorrhage 2 (CRASH-2) study was a placebo-con-
trolled trial, which enrolled over 20,000 trauma patients from 40 different trauma 
facilities around the world. The study included patients who presented with, or had 
significant risk of, major hemorrhage. Those randomized to the treatment arm were 
administered 1 g of intravenous TXA over 10 min within 8 h of the initial injury and 
an additional 1 g of IV TXA was infused over 8 h. The authors found this IV TXA 
protocol significantly decreased all-cause mortality secondary to bleeding [63]. 
While this data is not specific to extremity trauma, it does show efficacy in critically 
ill patients.
Several RCTs have translated the exploration of TXA in general trauma to the 
world of lower extremity trauma. Two recent meta-analyses have demonstrated 
that TXA can decrease perioperative blood loss, transfusions, and drops in hemo-
globin without reciprocal increased in thromboembolic events. All patients in these 
studies had suffered femoral neck fractures, intertrochanteic femur fractures, and 
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one study included calcaneus fractures. As with the data presented previously, 
several routes of administration were utilized with some studies included combina-
tion therapies (e.g., IV and topical TXA) [64, 65]. Interestingly, while these meta-
analyses found TXA to be effective in lowering transfusion rates and blood loss in 
lower energy trauma, a recent prospective trial by Spitler et al. found minimal effect 
of TXA in higher energy trauma including pelvic, acetabular, and femur fractures in 
younger patients [66].
Superiority of one method over another has not been demonstrated, but a 
complete list of suggested TXA protocols can be referred to in Table 3.
5. Hemostasis in orthopedic oncology
Orthopedic intervention in the world of oncology covers a vast array of proce-
dures which have a significant degree of overlap with the subspecialties listed above. 
Often, the goal of the orthopedic surgeon is to decrease or eliminate tumor burden 
through marginal resection, wide resection, and even amputation. These surgeries 
can be stand-alone, definitive treatments in the algorithm of patient care, or they 
can serve as adjuvant treatments to be used in addition to chemotherapy or radia-
tion. Orthopedic oncology also extends to the world of palliative medicine, where 
patients with metastatic disease may present with lesions of impending fracture 
that benefit from surgical stabilization.
While many of the strategies above may be employed during orthopedic tumor 
surgery, some have limited evidence. The sections below focus on techniques, tech-
nologies, or biosurgical applications that have not been addressed in the sections 
above, and that are specific to tumor surgery or have a preponderance of evidence 
in orthopedic oncology literature.
5.1 Tranexamic acid
As outlined above, TXA is a heavily studied compound that has demonstrated 
efficacy in decreasing blood loss across nearly all orthopedic subspecialties. 
Unfortunately, far fewer studies have explored the effects of TXA in major tumor 
surgery. One of the primary reasons for the lag in supporting data is that oncologic 
patients are often hypercoagulable at baseline and may have other secondary 
comorbidities induced by tumor burden or chemotherapeutic agents.
Endoprosthetic reconstruction is one arena of orthopedic oncology which has 
some supporting data. In a recent study by Haase et al., patients undergoing proxi-
mal femoral replacement, distal femoral replacement, or proximal tibial replace-
ment were given topical TXA intra-operatively. Compared to patients undergoing 
endoprothetic reconstruction without TXA, the TXA treatment group had lower 
perioperative blood loss, transfusion rates, and overall length of stay without 
increasing overall VTE rates. The authors cited a theoretical increased risk of 
thromboembolic complications as the reason for using topical TXA as opposed to IV 
or oral. The protocol involved diluting 1 g of TXA in 10 mL of normal saline which 
was then sprayed as a fine mist over the wound bed [67].
Only one study has evaluated the effects of intravenous TXA in orthopedic 
tumor resection. Damade et al. performed a retrospective case series on patients 
undergoing posterior laminectomy and fusion for metastatic spine disease. A 
15 mg/kg dose of TXA was infused at induction and 15 mg/kg/h was continuously 
infused for the next 8 h. Patients undergoing this treatment did have significantly 
lower transfusion rates compared to controls and, once adjusted for the number of 
fusion levels, also had lower perioperative blood loss [68].
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A summary of the TXA protocols in orthopedic oncology can be found in Table 3.  
While the preliminary data is promising, there is a significant gap in the literature 
supporting safety and efficacy of TXA in this patient population.
5.2 Microfibrillar collagen agents
Not uncommonly, orthopedic tumor surgery requires the use of bone graft to 
fill defects left behind from local or marginal resections. Autograft harvested from 
the iliac crest has many advantages over allograft counterparts, but can be associ-
ated with donor site morbidity including bleeding. Microfibrillar collagens (MFC) 
are bovine collagen derivatives that have used primarily to provide hemostasis 
at iliac crest donor sites. Though the exact mechanism of MFC agents is not fully 
understood, at least two theories have been supported by the literature. First, MFCs 
enhance platelet activity in a way similar to that of natural collagen, facilitating 
platelet adhesion to fibrin, platelet aggregation, and degranulation. Second, MFC 
agents complex with fibrin via the clot stabilizing factor XIIIa. It has been shown 
that even in thrombocytopenic environments, MFC agents can increase clot forma-
tion over controls [69].
Use of MFC agents in orthopedics is extremely limited and most of the data hails 
from spine literature where iliac crest autograft was formally the gold standard 
before modern grafting methods were developed. Craig et al. have the first reported 
human study of MFC agents in the orthopedic literature. Here, MFC agents were 
found to be equivalent to thrombin-soaked gel-foam in reducing hemovac output 
in the post-operative setting with no clinical evidence of immune reaction [70]. 
Intra-operatively, MFC agents have been shown to be better at reducing bone 
bleeding than control groups receiving no hemostatic agents, but does not reach 
the same level of effectiveness as gelatin paste of thrombin-soaked gel-foam [71]. 
More modern formulations combine MFCs, bovine-derived thrombin, and patient 
plasma into a composite gel applied to sites of bony bleeding. The patient’s plasma 
provides fibrinogen which is cleaved by the bovine thrombin into fibrin. This fibrin 
is then able to complex with the MFC’s creating a collagen-fibrin matrix. This 
self-contained mixture has been shown to significantly reduce total intra-operative 
blood loss compared to controls and may also decrease operative time [72].
Though several small, prospective case-control studies support the use of MFC 
agents for topical hemostasis, no large-scale RCT has evaluated its efficacy.
Please refer to Table 4 for the complete list of topical hemostatic agents used in 
orthopedic tumor surgery.
5.3 Pre-operative embolization
On occasion, surgeons can take advantage of tumor composition prior to opera-
tive intervention. For tumors which are highly vascular in nature, interventional 
radiologists may be able to ablate the blood supply, thus shrinking the tumor and 
decreasing the risk of hemorrhage in regions which are difficult to reach operatively. 
The most common embolizing agents are polyvinyl alcohol (PVA) and microcoils, 
and the most common metastatic lesions susceptible to embolization are renal cell 
carcinoma, thyroid carcinoma, and multiple myeloma. In extremity tumors, defini-
tive orthopedic intervention performed within 48 h of embolization can decrease 
transfusion requirements as well as perioperative blood loss in direct correlation to 
tumor size [73].
IR embolization can be especially helpful prior to decompressive spine surgery, 
but reliable data is difficult to decipher. Two RCTs with similar methodological cri-
teria came to differing conclusions on the effects of embolization on intra-operative 
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blood loss, transfusion requirements, and blood loss [74, 75]. A separate study 
found that decreases in blood loss only became significant if arterial supply was 
completely embolized versus partial or subtotal embolization [76].
Given that most evidence exploring pre-operative embolization of tumors prior 
to orthopedic intervention is level III or IV, no definitive conclusions can be made 
regarding efficacy. Despite this, there are certain circumstances where emboliza-
tion is likely beneficial including large tumors, highly vascular tumors, and tumors 
requiring large areas of resection. If the surgeon decides to pursue pre-operative 
embolization, it should be done within 24–72 h of planned orthopedic intervention 
and the surgeon should have a discussion with the interventional radiologist to 
determine if complete arterial occlusion can be achieved [77].
6. Conclusion
The topic of hemostasis in orthopedic surgery is immense, and the evidence 
behind certain principles is frequently limited. The sections above take a sub-
specialized approach to hemostasis encompassing technological breakthroughs, 
evolutions in surgical techniques, and novel biosurgical agents which can be used 
synergistically. Each subspecialty presents specific challenges when it comes to 
hemostasis, and even specific procedures may lend themselves to a high potential 
for blood loss. By remaining up to date with the most recent tools and techniques, 
as well as the evidence behind them, surgeons can continue to make informed 
decisions to minimize the risk of perioperative blood loss and thereby limit risk of 
post-operative complications.
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